OC
MBOT icon

Oppenheimer & Co’s Microbot Medical MBOT Stock Holding History

Oppenheimer & Co’s Portfolio MBOT Stock Details MBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10
Closed -$26K – 1429
2013
Q3 		$26K Buy
+10
New +$27.1K ﹤0.01% 1297

Other funds holding MBOT

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $578M AUM 41.69% 1-Year Est. Return

Oppenheimer & Co's MBOT Position: Q4 2013 in Review

Oppenheimer & Co sold out of Microbot Medical (MBOT) in Q4 2013, closing a stake of 10 shares — an estimated $26K sold.

Oppenheimer & Co first reported a position in MBOT in Q3 2013 and held it in 1 quarter. The position peaked at $26K in Q3 2013. 33 funds tracked by Wall St. Rank hold MBOT as of Q4 2013.

  • Oppenheimer & Co reported no remaining Microbot Medical position as of Q4 2013 after selling out during the quarter.
  • Oppenheimer & Co sold 10 Microbot Medical shares in Q4 2013, an estimated $26K.
  • Oppenheimer & Co first reported a position in Microbot Medical in Q3 2013 and held it in 1 quarter.
  • Oppenheimer & Co's Microbot Medical position peaked at $26K in Q3 2013.
  • 33 funds tracked by Wall St. Rank held Microbot Medical as of Q4 2013.

Based on Oppenheimer & Co's 13F filing for Q4 2013, filed 12 Feb 2014.